Reassessment of the role of cannabinoids in the management of pain

Current Opinion in Anaesthesiology

Volumn 20, Issue 5, 2007, Pages 473-477

  Beaulieu, Pierre ^a,c   Ware, Mark ^b  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Cannabinoids; Neuropathic pain; Postoperative pain; Tetrahydrocannabinol

Indexed keywords

CANNABIDIOL; CANNABINOID; CANNABIS; CODEINE; MORPHINE; NABILONE; TETRAHYDROCANNABINOL;

AWARENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE ASSOCIATION; DIZZINESS; DROWSINESS; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; HUMAN; MEMORY DISORDER; MOTOR NEURON DISEASE; MULTIPLE SCLEROSIS; NEUROPATHY; PAIN; POSTOPERATIVE PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SOMNOLENCE; SPASTICITY; UNSPECIFIED SIDE EFFECT; WEAKNESS; XEROSTOMIA;

ACUTE DISEASE; ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ANTI-ANXIETY AGENTS; CANNABINOIDS; CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; PAIN; PAIN MEASUREMENT; TETRAHYDROCANNABINOL;

EID: 34548693203     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e3282efd175     Document Type: Review

References (21)

1. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituant of haschich. J Am Chem Soc 1964; 86:1646-1647.
2. Lever IJ, Rice AS. Cannabinoids and pain. Handb Exp Pharmacol 2007; 177:265-306. This is a thorough and very recent review on the role of cannabinoids in pain management, including anatomical and functional data and signaling mechanisms involved in these actions.
3. Di Marzo V, Petrocellis LD. Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med 2006; 57:553-574. This is a review of recent clinical trials looking at the role of the cannabinoid (and endocannabinoid) system in medicine including pain management.
4. Piomelli D. The endocannabinoid system: A drug discovery perspective. Curr Opin Invest Drugs 2005; 6:672-679.
5. Hohmann AG, Suplita RL 2nd. Endocannabinoid mechanisms of pain modulation. AAPS J 2006; 8:E693-E708. This is an excellent review on how the endocannabinoid system, mainly anandamide and 2-arachidonoylglycerol, mediates stress-induced analgesia and nociceptive processing at supraspinal level.
6. Ware M, Beaulieu P. Cannabinoids for the treatment of pain: An update on recent clinical trials. Pain Res Manage 2005; 10 (SupplA):27A-30A.
7. Greenwald MK, Stitzer ML. Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend 2000; 59:261-275.
8. Naef M, Curatolo M, Petersen-Felix S, et al. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 2003; 105:79-88.
9. Buggy DJ, Toogood L, Maric S, et al. Lack of analgesic efficacy of oral delta-9-tetrahydrocannabinol in postoperative pain. Pain 2003; 106:169-172.
10. Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anesth 2006; 53:769-775.
11. Holdcroft A, Maze M, Doré C, et al. A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology 2006; 104:1040-1046.
12. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005; 76:1664-1669.
13. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005; 65:812-819.
14. Blake DR, Robson P, Ho M, et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology 2006; 45:50-52. The authors present further evidence of the efficacy of an oromucosal cannabis extract for pain, this time in rheumatoid arthritis.
15. Pinsger M, Schimetta W, Volc D, et al. Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain: a randomized controlled trial. Wien Klin Wochenschr 2006; 118:327-335.
16. Wissel J, Haydn T, Muller J, et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: A double-blind placebo-controlled cross-over trial. J Neurol 2006; 253:1337-1341.
17. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology 2007; 68:515-521. This was the first trial to report the analgesic efficacy of smoked cannabis for neuropathic pain associated with HIV/AIDS.
18. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003; 362:1517-1526.
19. Campbell FA, Tramer MR, Carroll D, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001; 323:13-16.
20. Attal N, Cruccu G, Haanpaa M, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 2006; 13:1153-1169.
21. Moulin DE, Clark AJ, Gilron I, et al. Pharmacological management of chronic neuropathic pain: consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag 2007; 12:13-21.